COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,541 Articles (22,881 medRxiv, 8,660 bioRxiv)

Most recent first Previous |  Page 2347: Articles 23461-23470  | Next

UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Walker, J. L., Grint, D. J., Strongman, H., Eggo, R. M., Peppa, M., Minassian, C., Mansfield, K. E., Rentsch, C. T., Douglas, I. J., Mathur, R., Wong, A., Quint, J. K., Andrews, N., Lopez Bernal, J., Scott, J. A., Ramsay, M., Smeeth, L., McDonald, H. I.
10.1101/2020.08.24.20179192 — Posted: 2020-08-26
The Effect of Area Deprivation on COVID-19 Risk in Louisiana
KC, M., Oral, E., Straif-Bourgeois, S., Rung, A. L., Peters, E. S.
10.1101/2020.08.24.20180893 — Posted: 2020-08-26
Sociodemographic disparities in knowledge, practices, and ability to comply with COVID-19 public health measures in Canada
Brankston, G., Merkley, E., Fisman, D. N., Tuite, A. R., Poljak, Z., Loewen, P. J., Greer, A. L.
10.1101/2020.08.24.20180919 — Posted: 2020-08-26
SARS-CoV-2 phylodynamics differentiates the effectiveness of non-pharmaceutical interventions
Rasigade, J.-P., Barray, A., Shapiro, J. T., Coquisart, C., Vigouroux, Y., Bal, A., Destras, G., Vanhems, P., Lina, B., Josset, L., Wirth, T.
10.1101/2020.08.24.20180927 — Posted: 2020-08-26
Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries
O'Driscoll, M., Ribeiro Dos Santos, G., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A., Cauchemez, S., Salje, H.
10.1101/2020.08.24.20180851 — Posted: 2020-08-26 Discussion: Onsite | Offsite
Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Butt, A. A., Coyle, P., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Abdul Rahim, H. F., Al Kuwari, M. G., Al Romaihi, H. E., Al Thani, S. M., Bertollini, R.
10.1101/2020.08.24.20179457 — Posted: 2020-08-26
COVID-19 and heart medications: What's the connection?
Saleknezhad, N., Khosravi, B., Anushiravani, A., Eslahi, M., Radmard, A. R., Sirusbakht, A., Pourabbas, S. M., Abdollahi, M., Kasaeian, A., Sorouri, M., Sima, A. R.
10.1101/2020.08.24.20174367 — Posted: 2020-08-26
Evidence of SARS-CoV-2 transcriptional activity in cardiomyocytes of COVID-19 patients without clinical signs of cardiac involvement
Bulfamante, G. P., Perrucci, G. L., Falleni, M., Sommariva, E., Tosi, D., Martinelli, C., Songia, P., Poggio, P., Carugo, S., Pompilio, G.
10.1101/2020.08.24.20170175 — Posted: 2020-08-26
Preventing disease after exposure to COVID-19 using hydroxychloroquine: A summary of a protocol for exploratory re-analysis of age and time-nuanced effects.
Wiseman, D. M., Kory, P., Mazzucco, D., Ramesh, M. S.
10.1101/2020.08.19.20178376 — Posted: 2020-08-26 Discussion: Onsite
Clinical Outcomes of Hospitalized Patients with COVID-19 on Therapeutic Anticoagulants
Patel, N. G., Bhasin, A., Feinglass, J. M., Belknap, S. M., Angarone, M. P., Cohen, E. R., Barsuk, J. H.
10.1101/2020.08.22.20179911 — Posted: 2020-08-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).